Institutional Equities

Similar documents
Power Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy

E&P To Stay Strong; Consumer Segment To Revive

Swaraj Engines. Institutional Equities. 2QFY18 Result Update ACCUMULATE

Bajaj Electricals. Institutional Equities. 3QFY15 Result Update

Crisil. Institutional Equities. 3QCY17 Result Update ACCUMULATE. Weak SME Rating Revenues & Currency Movement Play Spoilsport

Institutional Equities

Crompton Greaves. Institutional Equities. 4QFY15 Result Update ACCUMULATE. Overseas Losses Continue; More Business Exits Likely

Institutional Equities

Institutional Equities

Gillette India. Institutional Equities. 1QFY18 Result Update

Swiss Glascoat Equipments

Timken India. Institutional Equities. 4QFY16 Result Update BUY. Margin Expansion Leads To Huge Growth In Profit; Retain Buy

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

CARE Ratings. Institutional Equities. 2QFY18 Result Update BUY

93,707 77,814 90, NIM

Muthoot Finance. Institutional Equities. 1QFY18 Result Update. Gold Loan Business Continues To Glitter BUY. 10 August 2017

Colgate-Palmolive (India)

3,746 2,551 3, NIM

Cadila Healthcare. Institutional Equities. 3QFY15 Result Update UNDER REVIEW. Stable Performance. Sector: Pharmaceuticals CMP: Rs1,514

Atul Auto. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Automobile CMP: Rs445 Target Price: Rs489 Upside: 10% 23 August 2017

La Opala RG. Institutional Equities. 4QFY17 Result Update UNDER REVIEW. Revenues Soar, But Margins Take A Hit. Sector: Tableware CMP: Rs536

La Opala RG. Institutional Equities. 1QFY18 Result Update

9,807 8,007 9, NIM

ITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%

EBITDA 5,019 4,211 5, EBITDA

Punjab National Bank

Muthoot Finance. Institutional Equities. 2QFY18 Result Update BUY

Bata India. Institutional Equities. Management Meet Update. On Right Track ACCUMULATE. Sector: Retail CMP: Rs692 Target Price: 696 Upside: 1%

Institutional Equities

Punjab National Bank

Jamna Auto Industries

Punjab National Bank

9,251 7,812 8, NIM

Dabur India. Institutional Equities. 4QFY18 Result Update. Growth Volatility Is Still Fairly High ACCUMULATE

Hindustan Unilever. Institutional Equities. 4QFY18 Result Update

Power Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution

Sanofi India. Institutional Equities. 3QCY18 Result Update. Robust Performance BUY

Dabur India. Institutional Equities. 1QFY19 Result Update

Nestle India. Institutional Equities. 1QCY18 Result Update. Resurgence Continues BUY. Sector: FMCG CMP: Rs8,981 Target Price: Rs10,700 Upside: 19%

Hindustan Unilever. Institutional Equities. 1QFY19 Result Update

Institutional Equities

State Bank of India. Institutional Equities. 1QFY18 Result Update

Indian Oil Corporation

NESCO. Institutional Equities. Event Update. Revenues From Bombay Exhibition Centre May Take A Hit BUY

Sun Pharmaceutical Industries

Mold-Tek Packaging. Institutional Equities. Conference Update. Promising Growth Outlook BUY

Manappuram Finance. Institutional Equities. 3QFY17 Result Update BUY

Voltas. Institutional Equities. Management Meet Update ACCUMULATE. Sector: Capital Goods CMP: Rs309 Target Price: Rs325 Upside: 5% 23 December 2016

V-Guard Industries. Institutional Equities. Conference-call Update BUY. Sector: White Goods CMP: Rs914 Target Price: Rs1,109 Upside: 21%

Bata India. Institutional Equities. 1QFY19 Result Update BUY

Institutional Equities

Dalmia Bharat Enterprises

Voltas. Institutional Equities. 1QFY19 Result Update. EMPS Shines, UCP Proves Its Mettle Again ACCUMULATE

KEC International. Institutional Equities. Management Meet Update BUY. On Course Towards Recovery In Operating Margin

Institutional Equities

Thermax. Institutional Equities. 3QFY18 Result Update. Healthy Execution, But Margins Disappoint SELL

JBF Industries. Institutional Equities. 1QFY16 Result Update BUY. Healthy Gross Profit Growth, But Other Costs Higher; Retain Buy

KEC International. Institutional Equities. Management Meet Update. Healthy Order Inflow Traction Expected To Continue BUY

Persistent Systems. Institutional Equities. Management Meet Update SELL. Watson IOT Bet Risk/Reward More Muted Than Anticipated

Institutional Equities

Indian Oil Corporation

Eicher Motors. Institutional Equities. Management Meet Update BUY. Reuters: EICH.NS; Bloomberg: EIM IN

Hindustan Unilever. Institutional Equities. Company Update. Faster And Stronger BUY. Sector: FMCG CMP: Rs1,350 Target Price: Rs1,570 Upside: 16%

Tata Consultancy Services

26 October 2018 Reuters: MRTI.BO; Bloomberg: MSIL IN

Sequent Scientific. Institutional Equities. 1QFY19 Result Update BUY

Hindustan Unilever. Institutional Equities. 2QFY19 Result Update

EBITDA 5,076 3, , EBITDA

FY11 FY12 FY13E FY14E

South Indian Bank. Institutional Equities. 4QFY18 Result Update. Asset Quality Pain To Ease Hereafter BUY. 15 May 2018

TD Power Systems. Institutional Equities. Company Update BUY

Institutional Equities

Punjab National Bank

Hindustan Unilever. Institutional Equities. 3QFY18 Result Update BUY

Apar Industries. Institutional Equities. Management Meet Update. In Turnaround Mode; Retain Buy BUY

Punjab National Bank

Huhtamaki PPL. Institutional Equities. Management Meet Update NOT RATED. CMP: Rs186 Sector: Packaging. 16 September 2014

Arvind. Institutional Equities. Event Update BUY

IFB Industries. Institutional Equities. 3QFY18 Result Update. Healthy Revenues, Strong Gross Margin; Retain Buy BUY.

EBITDA 6,223 6,511 (4.4) 5, EBITDA

Institutional Equities

EBITDA 2,503 2,904 (13.8) 2,722 (8.0) EBITDA

Karnataka Bank. Institutional Equities. 4QFY18 Result Update. Plucky Bank And Low Hanging Fruit BUY. 17 May Reuters: KBNK.NS; Bloomberg: KBL IN

Mangalam Cement. Institutional Equities. 3QFY18 Result Update. Higher Operating costs Hurt Performance BUY

TVS Motor Company. Institutional Equities. 3QFY19 Result Update SELL

Whirlpool of India. Institutional Equities. Analyst Meet Update. Aims To Sustain Strong Growth Trajectory; Retain Buy BUY

Tech Mahindra. Institutional Equities. Company Interaction & Event Update SELL

Bharat Heavy Electricals

The Ramco Cements. Institutional Equities. Event Update BUY

ACC. Institutional Equities. Event Update. Capacity Expansion To Consolidate Presence In Central India ACCUMULATE

PNB Housing Finance. Institutional Equities. 4QFY18 Result Update BUY. Continued Display of Embedded Scalability. 4 May 2018

EBITDA 1,548 1,814 (14.7) 1,561 (0.8) EBITDA

Manappuram Finance. Institutional Equities. 3QFY18 Result Update. The Glitter Is Back In Gold Loans BUY. 9 February 2018

Institutional Equities

Dalmia Bharat Enterprises

2,09,057 1,85,859 2,17, (4.1) NIM

Colgate-Palmolive. Institutional Equities. Management Meet Update. Structural Story Strong As Ever BUY

Bharat Heavy Electricals

EBITDA 1,585 1,917 (17.3) 1,673 (5.2) EBITDA

Bata India. Institutional Equities. Management Meet Update. Likely Getting Into A Virtuous Cycle BUY

Transcription:

Management Meet Update Institutional Equities Kaya Reuters: KAYA.NS; Bloomberg: KAYA IN We interacted with the management of Kaya at an investor conference held by us recently. Following are the key takeaways: Competitive challenges remain high: Since inception, Kaya consistently faced competition from small standalone clinics/regional players. These unorganised players offer their services at a significant discount. However, it is difficult for small players to match up to Kaya s infrastructure and the range of services offered under a single roof. The management acknowledged that it is expecting the entry of new players in the organised segment, although at a regional level, and believes that this is positive for the industry as it will increase the overall awareness about skin care business in India which is still at a nascent stage. India business could witness break-even over the medium term: The management stated that specific steps are being taken to improve the performance of India business. In terms of services offered, anti-ageing, facial and pigmentation services are growing rapidly and the management believes that it will continue to grow in the same fashion, looking at the market potential. The management is extremely confident about the growth potential in the hair care segment and considers it as a major growth driver going forward. It is also focusing on product business, which accounts for of total turnover, by expanding its reach outside Kaya clinics. Kaya is increasing its presence on social media and focusing more on digital advertising. Also, it is going to renovate 20 top performing clinics in FY18 located at affluent areas to enhance the customer experience to further increase clinic throughput. It is targeting 14%- samestore sales growth or SSG over the next two to three years in India. The management did not give specific guidance on clinic expansion and stated that the company is opportunistically adding new clinics and relocating some of its old clinics. The Middle East (ME) business is somewhat stable and the management expects 8%-1 revenue growth in FY18. Saudi Arabia, which accounts for 2 of ME sales, witnessed a decline in 1QFY18 because of macroeconomic headwinds whereas the UAE business, which has 19 out of 23 clinics in ME, is performing well. To address the Saudi problem, Kaya is working on improving the customer experience and innovation-led products as well as services. No impact on pricing post GST on service business: Goods and Services Tax or GST has no impact on pricing of Kaya s service business. Small unorganised players, who were not registered in the pre-gst period, could witness an increase in pricing which could benefit Kaya to some extent. However, the product portfolio of Kaya, which forms of its revenues, will witness price hike of about 1-12% from September-October 2017 because of 28% GST as against 14%- tax in the pre-gst regime. The management stated that no player has increased the prices so far, but likely to do so by the end of the current quarter. Significant headroom to improve existing margin profile: Slowdown in clinic revenues and sustained increase in personnel and infrastructure costs significantly eroded Kaya s operating margin by 450bps-500bps in India. Kaya s focus on improving the top-line will bring down corporate overheads and advertising expenses which account for around 22% and 9% of revenues, respectively. The management is targeting corporate overheads in the range of 17%-18% over the near to medium term and 14%- in the long run through its cost optimisation intiatives. India business loss at EBITDA level has narrowed during the quarter because of withdrawal of excessive discounts. 30 August 2017 We are participating in AsiaMoney s Brokers Poll 2017. We would be pleased if you vote for us as the feedback helps us align our equity research offerings to meet your requirements. Click Here NOT RATED Sector: Consumer Goods CMP: Rs888 Abhishek Navalgund Research Associate abhishek.navalgund@nirmalbang.com +91-22-3926 8013 Key Data Current Shares O/S (mn) 13.0 Mkt Cap (Rsbn/US$mn) 11.6/180.7 52 Wk H / L (Rs) 1,205/650 Daily Vol. (3M NSE Avg.) 26,251 One Year Indexed Stock Performance 170 160 150 140 130 120 110 100 90 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Price Performance (%) KAYA NIFTY CNX NIFTY INDEX 1 M 6 M 1 Yr Kaya (2.8) 15.8 24.8 Nifty Index (2.2) 10.3 12.0 Source: Bloomberg

Note: Kaya has implemented Ind AS starting from FY18. Hence, as per SEBI circular to that effect dated 5th July 2017 the company has not reported consolidated numbers for 1QFY18. Hence, ME and consolidated numbers could not be plotted in the tables/graphs below. Exhibit 1: Margin and growth profile Particulars March 2016 June 2016 September 2016 December 2016 March 20-17 June 2017 EBITDA margin % - overall 4 2 5 (1) 3 N.A. PAT margin % - overall 1-3 (3) 0.2 N.A. India margins (%) EBITDA - India (4) (10) (4) (12) (10) (6) PAT - India (5) (6) (4) (13) (11) (6) ME region (%) EBITDA - ME region 11 12 13 9 13 N.A. PAT - ME region 7 8 9 5 10 N.A. SSG growth (%) Overall SSG 10 11 13 (1) 6 N.A. India SSG - 8 5 (7) 4 9 ME region SSG 20 14 20 6 7 N.A. Customer count (%) Customer count - India (3) 2 8 (2) 10 2 Customer count ME region 22 15 7 (2) (5) N.A. Ticket size (%) Ticket size - India 4 5-3 (2) 4 Ticket size ME region (6) - 3 3 13 N.A. Overall revenue growth (%) 17 16 16 2 11 N.A. Revenue growth India (%) 8 13 8 (4) 4 5 Revenue growth ME region (%) 28 20 24 8 17 N.A. Exhibit 2: Revenue growth trend 3 2 2 Exhibit 3: EBITDA margin trend 2 1 1-1 Overall India ME -1 - Overall EBITDA % India EBITDA % ME EBITDA % Exhibit 4: SSG trend 2 2 1-1 Overall India ME 2 Kaya

Exhibit 5: Peer comparison Company CMP (Rs) Mkt. cap. (US$mn) P/Sales (x) EV/EBITDA (x) P/E (x) Sales FY17 FY18E FY19E FY17 FY18E FY19E FY17 FY18E FY19E CAGR % EBITDA CAGR % EPS CAGR % Kaya 884 180 2.5 2.5 2.2 63.9 93.6 49.1 N.R. 205.5 80.3 12.6 12.5 N.A. Hindustan Unilever 1,200 40,679 8.0 7.1 6.3 30.8 35.1 30.2 57.9 51.3 43.5 12.4 15.3 15.5 Dabur India 313 8,629 7.2 6.6 5.9 32.3 33.9 29.7 43.1 39.3 34.4 10.6 10.8 12.1 Emami 1,077 3,829 9.8 8.9 7.6 32.3 30.5 26.1 71.9 39.7 33.7 13.8 12.0 46.0 Source: Bloomberg, Nirmal Bang Institutional Research 3 Kaya

Financials (consolidated) Exhibit 6: Income statement Net sales 2,903 3,323 3,699 4,102 Growth (%) N.A 14.5 11.3 10.9 COGS 318 354 393 370 Staff costs 1,017 1,061 1,287 1,473 Rent 376 406 473 520 Advertising and sales promotion 225 235 260 286 Other expenses 850 939 1153 1304 Total expenditure 2,786 2,995 3,566 3,952 EBITDA 117 328 133 150 Growth (%) N.A 179.6 (59.4) 12.7 EBITDA margin (%) 4.0 9.9 3.6 3.7 Other income 35 154 124 103 Exceptional items (373) (48) - - Interest costs 2 0.2 0.2 53.6 Depreciation 95 116 169 201 Profit before tax (317) 318 88 (2) Growth (%) N.A (200.2) (72.3) (101.9) Tax - - - - Effective tax rate (%) 0.1 - - - Net profit from continuing (317) 318 88 (1.7) operations Profit from discontinuing 691 - - - operations Total 374 318 88 (2) Growth (%) N.A (200) (72) (101.9) Minority interest - - 1 6 Adjusted PAT 374 318 87 (8.1) Growth (%) N.A (15.0) (72.5) (109.3) Exhibit 8: Balance sheet Equity 178 129 129 130 Reserves 650 2,217 2,384 2,375 Net worth 828 2,346 2,513 2,505 Minority interest - - 5 15 Total loans 1,132 - - 301 Deferred tax liability - - - - Other Long term liabilities 76 94 126 175 Total liabilities 3,290 3,727 4,065 4,311 Gross block 1,583 1,821 2,232 3,644 Depreciation/Impairment 1,562 1,291 1,440 1,456 Net block 21 530 792 2,188 Capital work-in-progress 6 32 24 15 Goodwill on consolidation 551 591 701 - Total Non current assets 1,048 1,375 1,759 2,458 Inventories 247 335 529 502 Debtors 4 4 15 20 Cash 142 276 278 156 Current investments 1,685 1,519 882 715 Total current assets 2,242 2,352 2,306 1,853 Creditors 173 287 376 345 Other current liabilities 1,081 1,000 1,045 934 Total current liabilities 1,254 1,287 1,421 1425 Net current assets 988 1,065 885 427 Total assets 3,290 3,727 4,065 4,311 Exhibit 7: Cash flow PBT 461 318 88 (2) Depreciation 95 116 169 201 Adjustments (167) (144) (108) (95) (Inc.)/dec. in working capital 547 12 (99) (165) Tax paid (18) (9) (2) 1 Cash flow from operations 918 292 47 (60) Capital expenditure (-) (163) (359) (421) (254) Free cash flow 755 (66) (374) (314) (Purchase)/sale of investments (1244) 330 728 234 Other investment income 1 3 4 (73) Cash flow from investing activities (115) (165) (63) (408) Proceeds of share capital - - - 38 Increase/ (decrease) in loan funds (708) - - 301 Interest paid (23) - - (5) Cash from financial activities (730) - - 334 Opening cash balance 252 142 276 278 Closing cash balance 142 276 278 153 Change in cash balance (110) 135 1 (125) Exhibit 9: Key ratios Y/E March FY14 FY15 FY16 FY17 Per share (Rs) EPS 21 25 7 (1) Book value 47 182 195 192 Valuation (x) P/E N.A N.A 127.1 N.R. P/sales N.A N.A 3.0 2.5 P/BV N.A N.A 4.4 4.0 EV/EBITDA N.A N.A 74.7 63.9 EV/sales N.A N.A 2.7 2.3 Return ratios (%) RoCE 1.1 9.0 (1.4) (1.8) RoE 45.2 13.6 3.5 (0.3) Margins (%) EBITDA 4.0 9.9 3.6 3.7 EBIT 0.8 6.4 (1.0) (1.2) PBT (10.8) 9.1 2.3 (0.0) PAT 12.7 9.1 2.3 (0.2) Turnover ratios Asset turnover ratio (x) 0.9 0.9 0.9 1.0 Avg. collection period (days) - - 1 2 Avg. inventory period (days) 31 32 43 46 Avg. payment period (days) 22 25 33 32 Solvency ratios (x) Debt-equity 1.4 - - 0.1 Growth (%) Sales N.A 14.5 11.3 10.9 EBITDA N.A 179.6 (59.4) 12.7 PAT N.A (15.0) (72.5) (109.3) 4 Kaya

Disclaimer Stock Ratings Absolute Returns BUY > ACCUMULATE to SELL < This report is published by Nirmal Bang s Institutional Equities Research desk. Nirmal Bang group has other business units with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets. Reports based on technical and derivative analysis may not match with reports based on a company's fundamental analysis. This report is for the personal information of the authorised recipient and is not for public distribution. This should not be reproduced or redistributed to any other person or in any form. This report is for the general information for the clients of Nirmal Bang Equities Pvt. Ltd., a division of Nirmal Bang, and should not be construed as an offer or solicitation of an offer to buy/sell any securities. We have exercised due diligence in checking the correctness and authenticity of the information contained herein, so far as it relates to current and historical information, but do not guarantee its accuracy or completeness. The opinions expressed are our current opinions as of the date appearing in the material and may be subject to change from time to time without notice. Nirmal Bang or any persons connected with it do not accept any liability arising from the use of this document or the information contained therein. The recipients of this material should rely on their own judgment and take their own professional advice before acting on this information. Nirmal Bang or any of its connected persons including its directors or subsidiaries or associates or employees or agents shall not be in any way responsible for any loss or damage that may arise to any person/s from any inadvertent error in the information contained, views and opinions expressed in this publication. Nirmal Bang Equities Private Limited (hereinafter referred to as NBEPL ) is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited. NBEPL has registered with SEBI as a Research Entity in terms of SEBI (Research Analyst) Regulations, 2014. (Registration No: INH000001436-19.08.2015 to 18.08.2020). NBEPL or its associates including its relatives/analyst do not hold any financial interest/beneficial ownership of more than 1% in the company covered by Analyst. NBEPL or its associates/analyst has not received any compensation from the company covered by Analyst during the past twelve months. NBEPL /analyst has not served as an officer, director or employee of company covered by Analyst and has not been engaged in market-making activity of the company covered by Analyst. The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. Access all our reports on Bloomberg, Thomson Reuters and Factset. Team Details: Name Email Id Direct Line Rahul Arora CEO rahul.arora@nirmalbang.com - Girish Pai Head of Research girish.pai@nirmalbang.com +91 22 3926 8017 / 18 Dealing Ravi Jagtiani Dealing Desk ravi.jagtiani@nirmalbang.com +91 22 3926 8230, +91 22 6636 8833 Pradeep Kasat Dealing Desk pradeep.kasat@nirmalbang.com +91 22 3926 8100/8101, +91 22 6636 8831 Michael Pillai Dealing Desk michael.pillai@nirmalbang.com +91 22 3926 8102/8103, +91 22 6636 8830 Atul Vitha Dealing Desk atul.vitha@nirmalbang.com +91 22 3926 8071 / +91 22 3926 8226 Nirmal Bang Equities Pvt. Ltd. Correspondence Address B-2, 301/302, Marathon Innova, Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-400013. Board No. : 91 22 3926 8000/1; Fax. : 022 3926 8010 5 Kaya